Health
Moffitt researchers use mathematical modeling to help explain outcomes of CAR T-cell therapy – News-Medical.Net
Chimeric antigen receptor T-cell therapy, or CAR T, is a relatively new type of therapy approved to treat several types of aggressive B cell leukemias and lymphomas….
Chimeric antigen receptor T-cell therapy, or CAR T, is a relatively new type of therapy approved to treat several types of aggressive B cell leukemias and lymphomas. Many patients have strong responses to CAR T; however, some have only a short response and develop disease progression quickly. Unfortunately, it is not completely understood why these patients have progression. In an article published in Proceedings of the Royal Society B, Moffitt Cancer Center researchers use mathematical modeling…
-
Business15 hours agoThis ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
Business19 hours agoThis leading broker thinks the CSL share price can climb 40%
-
Business12 hours agoDicker Data rides the AI trend to double digit growth
-
Business15 hours agoForget CBA shares, this ASX 200 financials stock could be a better buy